Skip to main content

Table 2 Effects on outcomes after six and 12 months of follow-up for both treatment groups according to the intention-to-treat principle

From: One-year effects of two intensive inpatient treatments for severely obese children and adolescents

 

Short-stay

Long-stay

Crude

Adjusted

Mean (SD)

Mean (SD)

Beta (95 % CI)

Beta (95 % CI)

Primary outcome measure

SDS-BMI

 Baseline

3.4 (0.4)

3.4 (0.4)

  

 6-months

3.1 (0.5)

2.9 (0.6)

0.22 (0.09; 0.35)

0.23 (0.09; 0.36)

 12-months

3.1 (0.6)

2.9 (0.7)

0.18 (−0.03; 0.40)

0.18 (−0.04; 0.40)

 Overall effecta

  

0.10 (−0.11; 0.31)

0.15 (−0.06; 0.35)

Secondary outcomes

SDS-waist circumference

 Baseline

3.2 (0.4)

3.1 (0.4)

  

 6-months

2.7 (0.5)

2.5 (0.5)

0.13 (−0.03; 0.30)

0.12 (−0.05; 0.30)

 12-months

2.7 (0.7)

2.5 (0.7)

0.08 (−0.18; 0.34)

0.02 (−0.23; 0.27)

 Overall effecta

  

0.14 (−0.07; 0.35)

0.15 (−0.07; 0.37)

Systolic blood pressure (mmHg)

 Baseline

122.7 (12.3)

121.1 (13.4)

  

 6-months

117.1 (13.9)

116.7 (13.4)

−0.63 (−4.73; 3.48)

0.17 (−3.98; 4.33)

 12-months

118.4 (11.2)

120.0 (15.3)

−2.84 (−7.27; 1.60)

−2.25 (−6.95; 2.45)

 Overall effecta

  

0.59 (−4.65; 5.82)

0.44 (−4.86; 5.75)

Diastolic blood pressure (mmHg)

 Baseline

75.7 (9.9)

78.0 (12.3)

  

 6-months

68.5 (7.9)

68.3 (11.2)

1.49 (−2.04; 5.02)

0.47 (−3.17; 4.11)

 12-months

68.6 (8.1)

67.1 (12.0)

3.02 (−0.72; 6.76)

2.35 (−1.64; 6.34)

 Overall effecta

  

−0.42 (−4.40, 3.56)

−1.21 (−5.21, 2.80)

Fasting insulin (μU/L)

 Baseline

13.8 (9.3)

14.6 (9,5)

  

 6-months

11.9 (9.3)

12.9 (10.8)

−0.98 (−4.50; 2.55)

−1.41 (−5.20; 2.39)

 12-months

11.7 (9.1)

14.1 (10.1)

−1.27 (−4.25; 1.70)

−2.15 (−5.39; 1.09)

 Overall effecta

  

−1.10 (−3.60; 1.40)

−2.30 (−5.75; 1.16)

2 h-insulin (μU/L)

 Baseline

70.7 (49.9)

60.8 (36.8)

  

 6-months

63.0 (56.9)

52.4 (37.7)

1.16 (−17.21; 19.52)

−0.80 (−19.82; 18.22)

 12-months

67.9 (47.4)

65.3 (54.5)

−0.54 (−23.38; 22.48)

−2.89 (−26.49; 20.71)

 Overall effecta

  

0.65 (−15.50; 16.80)

1.86 (−13.59; 17.31)

Fasting glucose (mmol/L)

 Baseline

4.7 (0.4)

4.7 (0.3)

  

 6-months

4.8 (0.4)

4.8 (0.3)

0.03 (−0.11; 0.16)

0.02 (−0.13; 0.16)

 12-months

4.8 (0.4)

4.9 (0.3)

−0.06 (−0.19; 0.08)

−0.01 (−0.13; 0.12)

 Overall effecta

  

−0.04 (−0.16; 0.08)

−0.02 (−0.14; 0.10)

2 h-glucose (mmol/L)

 Baseline

6.0 (1.2)

5.6 (1.1)

  

 6-months

5.4 (1.1)

5.1 (1.0)

−0.02 (−0.47; 0.42)

−0.02 (−0.51; 0.47)

 12-months

5.8 (1.1)

5.3 (1.4)

0.32 (−0.24; 0.87)

0.29 (−0.32; 0.89)

 Overall effecta

  

0.35 (−0.06; 0.77)

0.35 (−0.07; 0.76)

HDL-cholesterol (mmol/L)

 Baseline

1.1 (0.3)

1.0 (0.2)

  

 6-months

1.2 (0.3)

1.1 (0.2)

0.04 (−0.02; 0.11)

0.04 (−0.03; 0.11)

 12-months

1.2 (0.3)

1.2 (0.3)

−0.07 (−0.17; 0.04)

−0.04 (−0.14; 0.07)

 Overall effecta

  

0.07 (−0.03; 0.17)

0.09 (−0.02; 0.20)

Triglycerides (mmol/L)

 Baseline

1.0 (0.6)

1.0 (0.5)

  

 6-months

1.1 (1.0)

1.0 (0.5)

0.09 (−0.14, 0.31)

0.04 (−0.15, 0.22)

 12-months

1.2 (0.9)

1.1 (0.7)

0.09 (−0.18, 0.35)

0.04 (−0.22, 0.29)

 Overall effecta

  

0.09 (−0.18, 0.37)

0.06 (−0.17, 0.29)

HOMA-IR

 Baseline

2.9 (2.0)

3.1 (2.1)

  

 6-months

2.5 (2.0)

2.8 (2.4)

−0.17 (−0.96; 0.61)

−0.26 (−1.11; 0.59)

 12-months

2.5 (2.0)

3.1 (2.4)

−0.33 (−1.02, 0.37)

−0.44 (−1.17, 0.30)

 Overall effecta

  

−0.31 (−1.11; 0.49)

−0.52 (−1.28; 0.25)

  1. Adjusted models corrected for baseline, sex, ethnicity, and economic status
  2. Abbreviations: CI confidence interval, SD standard deviation, SDS-BMI standard deviation of body mass index, SDS-waist circumferencestandard deviation of waist circumference, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment for insulin resistance
  3. aOverall effect can be interpreted as the average difference over time between the two treatment groups